Eli Lilly, Incyte say filed NDA for rheumatoid arthritis drug

19 January 2016

US drug major Eli Lilly (NYSE: LLY) and Incyte Corp (Nasdaq: INCY) on Tuesday announced that Lilly has submitted a New Drug Application to the US Food and Drug Administration for the approval of baricitinib to treat rheumatoid arthritis (RA).

Following the application Incyte is now set to receive a milestone payment of $35 million from Lilly related to the submission, the companies said in a joint statement. If baricitinib is granted US regulatory approval, Incyte will receive a milestone payment of $100 million from Lilly. Incyte could earn additional global regulatory as well as sales-based milestone payments and be eligible for royalties on global net sales of baricitinib.

David Ricks, president of Lilly Bio-Medicines, said: "Lilly's collaboration with Incyte has produced a rigorous Phase III program and, if approved, the potential of a promising new treatment option for people with RA."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK